Severe hyperglycemia has emerged as a common side effect among patients with PIK3CA-mutated breast cancer treated with the PI3K inhibitor alpelisib (Piqray), especially patients treated outside a ...

Monday, Relay Therapeutics Inc. (NASDAQ:RLAY) shared interim data for RLY-2608 from the ReDiscover study of RLY-2608 alone, in combination with fulvestrant, and in combination with fulvestrant and ...

BUFFALO, NY-April 25, 2023 – A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 7, entitled, ...

Simultaneous inhibition of phosphoinositide 3-kinase (PI3K) and histone deacetylase (HDAC) is considered a good strategy in cancer treatment, although current PI3K/HDAC dual inhibitors have ...

Molecular testing utilization in patients with advanced non-small cell lung cancer (NSCLC) in Washington (WA) state. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract ...

The FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi) for use in combination with palbociclib (Ibrance) and fulvestrant to treat locally advanced, PIK3CA ...

Immunohistochemical identification of SDHA-mutant gastrointestinal stromal tumors (GISTs). Neoadjuvant treatment of locally advanced GIST: Results of APOLLON, a prospective, open label phase II study ...

Roche’s pitch to reset the standard of care in a breast cancer population has cleared a late-phase hurdle. The drugmaker’s attempt to improve on Novartis’ Piqray and deliver a first-line PI3K ...

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third major transaction announced on the first day of the JP Morgan ...

Kazia Therapeutics Ltd. raised AU$50 million (US$33.15 million) in a private placement of equity securities to advance lead candidate paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor in clinical ...